We are human. We are digital. We are both. The digital mindset and digital transformation, once heavily focused in marketing, advertising, finance, and retail also drives advances in Life Sciences.
Computational Biology, Bioinformatics, and statistics. If you’re going to solve biological problems with data, you need Biostatistics. Just like you need a Data Engineer to create the parameters from which to build the structure of your Data, you need a Biostatistician to lay the groundwork to study the life in Life Sciences. This information can be infused in a variety of industries, not the least of which is medicine.
We haven’t reached immortality yet, but we’re well on our way.
Route to the Role of Biostatistician
If numbers at the pixel level are your cup of tea, then this role was made for you. At its core, Biostatistics is the application of statistics to range of topics in biology. It is for the numbers geek with a creative streak, and encompasses the design of biological elements; the gathering and analyzing Data from experiments and offering solutions to problems in medicine, health, and many more.
The educational component of this role is more often not at the PhD level and, as pharma works to beat the back the opioid crisis, Biostatisticians are on the rise. Not the least of which to reach out is the Food and Drug Administration (FDA), who have turned to scientists at UNC to fill knowledge gaps
Pharma may be in the news, but Biostatistics go well beyond this single focus in areas such as genetics, potential open source biological databases, and digital transformation throughout the medical fields. Want to know what else is in store for the Life Sciences?
Trends to Watch
The 2019 Global Life Sciences Outlook
offers deeper insight into the following trends and offers a glimpse into the next wave of digital transformation with a focus on Biostatistics, Bioinformatics, and Computational Biology endeavors.
Move over pharma legacy culture. There are new players in town. From tech giants diversifying into health care to small business startups controlling assets through its lifecycle, the next generation is shaking things up.
The hunt for next gen meds has begun in answer to declining R&D returns making the case for strategic deal making a key innovation source for companies.
- Connection and integration of medical devices into existing care pathways across the Internet of Medical Things (IoMT) ecoysystem.
- Outsiders become insiders as increasing security risks spur companies to safeguard their data. Outsourcing expertise in AI, cognitive automation, and cloud computing for peace of mind.
- Cross-pollination of transformative technologies – physical, digital, and biological – to help forward thinking pharma companies evolve from pilots to determining how new technologies can best add value using:Artificial Intelligence (AI)
- DIY diagnostics and virtual care
- Internet of Medical Things (IoMT)
- Software-as-a-Medical-Device (SaMD)